Group Information (Tables)

12 Months Ended

Dec. 31, 2022

Interests In Other Entities [Abstract]

Summary of Information about Subsidiaries

The consolidated financial statements include the following subsidiaries:

			% equity interest
Name	Country of incorporation	Registered office	December 31, 2022			December 31, 2021
BioNTech BioNTainer Holding GmbH	Germany	Mainz		100	%		n/a	(1)
BioNTech Cell & Gene Therapies GmbH	Germany	Mainz		100	%		100	%
BioNTech Delivery Technologies GmbH	Germany	Halle		100	%		100	%
BioNTech Diagnostics GmbH	Germany	Mainz		100	%		100	%
BioNTech Europe GmbH	Germany	Mainz		100	%		100	%
BioNTech Individualized mRNA Manufacturing GmbH i.G.	Germany	Mainz		100	%		n/a	(1)
BioNTech Innovation GmbH	Germany	Mainz		100	%		100	%
BioNTech Innovative Manufacturing Services GmbH	Germany	Idar-Oberstein		100	%		100	%
BioNTech Idar-Oberstein Services GmbH	Germany	Idar-Oberstein		100	%		n/a	(1)
BioNTech Manufacturing GmbH	Germany	Mainz		100	%		100	%
BioNTech Manufacturing Marburg GmbH	Germany	Marburg		100	%		100	%
BioNTech Innovation and Services Marburg GmbH	Germany	Marburg		100	%		100	%
JPT Peptide Technologies GmbH	Germany	Berlin		100	%		100	%
NT Security and Services GmbH	Germany	Mainz		100	%		n/a	(1)
reSano GmbH	Germany	Mainz		100	%		100	%
BioNTech Real Estate Holding GmbH	Germany	Holzkirchen		100	%		100	%
BioNTech Real Estate Verwaltungs GmbH	Germany	Holzkirchen		100	%		100	%
BioNTech Real Estate GmbH & Co. KG	Germany	Holzkirchen		100	%		100	%
BioNTech Real Estate An der Goldgrube GmbH & Co. KG	Germany	Holzkirchen		100	%		100	%
BioNTech Real Estate Haus Vier GmbH & Co. KG	Germany	Holzkirchen		100	%		100	%
BioNTech Real Estate Adam-Opel-Straße GmbH & Co. KG	Germany	Holzkirchen		100	%		100	%
BioNTech Real Estate An der Goldgrube 12 GmbH & Co. KG	Germany	Holzkirchen		100	%		100	%
BioNTech Australia Pty Ltd	Australia	Melbourne		100	%		n/a	(1)
BioNTech R&D (Austria) GmbH	Austria	Vienna		100	%		100	%
BioNTech (Shanghai) Pharmaceuticals Co. Ltd.	China	Shanghai		100	%		100	%
BioNTech Rwanda Ltd.	Rwanda	Kigali		100	%		n/a	(1)
BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.	Singapore	Singapore		100	%		100	%
BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi	Turkey	Istanbul		100	%		100	%
BioNTech UK Limited	United Kingdom	London (previously  Reading)		100	%		100	%
BioNTech Research and Development, Inc.	United States	Cambridge		100	%		100	%
BioNTech USA Holding, LLC	United States	Cambridge		100	%		100	%
BioNTech US Inc.	United States	Cambridge		100	%		100	%
JPT Peptide Technologies Inc.	United States	Cambridge		100	%		100	%

(1)  Has been incorporated during the year ended December 31, 2022.

Summary of Information about Parent Company

ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany, and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enabled it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM.

			Ownership of ordinary shares in BioNTech (in %)
Name	Country of incorporation	Registered office	December 31, 2022			December 31, 2021
AT Impf GmbH	Germany	Munich		43.42	%		43.75	%

Summary of Information about Entity with Significant Influence Over Group

Medine GmbH, Mainz, owned the following percentage of ordinary shares in BioNTech at the following dates as indicated:

			Ownership of ordinary shares in BioNTech (in %)
Name	Country of incorporation	Registered office	December 31, 2022			December 31, 2021
Medine GmbH	Germany	Mainz		17.38	%		17.11	%